💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Top Stock Reports For Halliburton, Boston Scientific & Anheuser-Busch

Published 06/29/2017, 12:28 AM
Updated 07/09/2023, 06:31 AM
HAL
-
GPC
-
HSY
-
BSX
-
SBMRF
-

Thursday June 29 2017

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Halliburton (HAL), Boston Scientific (BSX), and Anheuser-Busch (BUD).These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Halliburton’s shares have suffered this year, as have shares of all oil-related companies, to reflect the commodity's price slide and uneven outlook. That said, it has done better than its peers (the stock is down -22.3% in the year-to-date period vs. -26.5% decline for the Zacks Oil & Gas-Field Services industry), reflecting improved utilization on the back of surging North American rig count. Cost saving initiatives undertaken during the downturn have also helped the company navigate a difficult operating environment. However, sluggish international outlook – reflecting lower activity and pricing pressure – is expected to dampen investor confidence. Moreover, with the failure of BHI acquisition, HAL had to book a massive $3.5 billion in breakup charges that stretched its balance sheet. The Zacks analyst thinks investors should wait for a better entry point before buying shares in HAL.

(You can read the full research report on Halliburton here >>>).

Shares of Boston Scientific have outperformed the Zacks Medical - Products industry in the year-to-date period, gaining +30% vs. +20.9%. The company is leaving no stone unturned to strengthen its core businesses and is investing in innovations and global markets. Boston Scientific recently received CE mark for its Vercise Gevia DBS System which is expected to boost its European business. The favorable clinical BT study is also encouraging. Increased top line guidance for 2017 also buoys optimism. On the flip side, while an adverse foreign exchange situation continues to pose challenges, the Zacks analyst thinks the company’s recall of one of its prime products, the Lotus range of heart devices is a major concern. Also dull defibrillator sale within core CRM continues to remain a drag for the overall growth.

(You can read the full research report on Boston Scientific here >>>).

Anheuser-Busch’ shares have underperformed the Zacks Beverages - Alcohol industry over the last three months, gaining +1.7% vs. an increase of +2.2%. The Zacks analyst likes the company’s robust brand portfolio and solid geographical reach. The company’s focus on developing near beer alternatives, expanding in the craft beer space and undertaking innovations are other positives. Moreover, the company seeks growth via mergers and acquisitions, as evident from its Sab Miller buyout, after which it is likely to control about one-thirds of the beer industry. AB InBev’s last reported quarter marked its fifth straight earnings miss, as results were hurt by currency headwinds and persistent weakness in Brazil. Also, estimates have declined, since management projected increased cost of sales for 2017. Additionally, a tough macroeconomic environment and volatility in some core regions remain concerns for the company. (You can read the full research report on Anheuser-Busch here >>>).

Other noteworthy reports we are featuring today include Hershey (HSY), Kraft Heinz (KHC) and Genuine Parts (GPC).

The Best & Worst of Zacks

Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 11X worse than the market. See these critical buys and sells free >>

Brian Hamilton

Investment Research Coordinator

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

Sarepta (SRPT) Receives a Huge Boost from Exondys 51 Approval

Per the Zacks analyst, the FDA approval of Exondys 51, the first DMD treatment to gain approval in the U.S, was a huge boost for Sarepta.

Apogee (APOG) Growing on Architectural Markets, ECFO Buyout

The covering analyst expects Apogee to gain from the EFCO acquisition and growing architectural market. Focus on operational improvements and expansion in geographies are also likely to fuel growth.

FactSet (FDS) Revenues to Benefit from BISAM & IDMS Buyouts

The Zacks analyst believes that the buyouts will remain a key revenue driver for the company over the long-run.

Darden's (DRI) Olive Garden Sales Strong, Industry Woes Stay

Per the Zacks analyst, initiatives at Olive Garden like simpler kitchen system, menu innovation, digital changes and To-Go business could boost sales despite the tough restaurant industry backdrop.

TC PipeLines (TCP) Banks On Iroquois Buyout Amid Debt Woes

While the covering analyst believes that the recent acquisition of Iroquois and PNGTS is likely to boost the earnings and cash flows of TC PipeLines, the high leverage ratio of 60% remains a concern.

High Costs Hit Genuine Parts (GPC), New Products to Boost

Per the Zacks analyst, the high costs related to labor and delivery are likely to hit Genuine Parts.

New Launches to Aid Autoliv (ALV), Electronics Unit a Woe

Per the Zacks Analyst, Autoliv's new product launches, acquisitions and JVs are likely to improve its sales.

New Upgrades

Investments in Regulated Assets Lifting Alliant (LNT)

The Zacks analyst believes Alliant Energy is benefiting from consistent investment in its regulated assets and ongoing economic development in its service territories.

Cypress (CY) Drives On Strong Product Portfolio, Auto & IoT

The Zacks analyst believes that Cypress strong product portfolio, new design wins, strength in the auto segment and expansion in the IoT market are encouraging.

Buyout of MTS, Wireless Subscriber Gain Boosts BCE (BCE)

Per the covering analyst, the buyout of Manitoba Telecom Services and other strategic business moves have boosted the subscriber gain in the BCE's wireless segment.

New Downgrades

Currency Exposure, Soft US sales Hurting Hain Celestial (HAIN)

Per the Zacks analyst, Hain Celestial top line is being hurt by soft US segment and foreign currency headwinds. In the final quarter, it expects currency headwinds to lower sales by $40 million.

Kraft Heinz (KHC) Sales Hit Hard by Organic Food Trend

The covering analyst stresses that Kraft Heinz is witnessing top-line weakness for the past several quarters owing to the shift in consumer preference toward natural and organic food.

Weak Category Trend and Soft Global Sales Hit Hershey (HSY)

Per the Zacks analyst, Hershey's sales trends lack luster due to weak category trends and soft international growth. Persistent macroeconomic challenges in China continue to hurt results.



The Kraft Heinz Company (KHC): Free Stock Analysis Report

Hershey Company (The) (NYSE:HSY): Free Stock Analysis Report

Halliburton Company (NYSE:HAL): Free Stock Analysis Report

Genuine Parts Company (NYSE:GPC): Free Stock Analysis Report

Anheuser-Busch Inbev SA (BUD): Free Stock Analysis Report

Boston Scientific Corporation (NYSE:BSX): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.